We are pleased to introduce our first suite of profiling services designed to detect biologically-active cytokines. Like our cell-based kinase assays, these services leverage the differential viability of various primary and transformed cells in the presence and absence of specific cytokines. You provide a sample containing your (known or unknown) cytokine of interest and we’ll tell you how much activity is present (in standardized international units). Be sure to enter our contest for a chance to win an Amazon Echo Dot!
In this issue, we introduce our new KinoCore3 and KinoCore10 services. The KinoCore panel contains a subset of our assays that we’ve chosen to best capture the pattern of responses exhibited by their related family members within the tyrosine kinome. Now you can evaluate the (likely) global tyrosine kinase inhibitory activities of your compound using only 13 of our assays. Best of all, submit compounds before the end of the year and receive 30% off your first order. Details are just a click away!
We all know that kinase inhibitors have proven to be potent agents in the treatment of oncogenic lesions. Likewise, we have encountered numerous examples of therapeutic resistance emerging due to somatic mutations (often in the “gatekeeper” region) that reduce or eliminate therapeutic efficacy. In our summer newsletter, we explore the recently published findings of Wylie and colleagues regarding the development and application of the allosteric inhibitor ABL001. We think what they found is very exciting – and hope you will too!
In this issue we explore a sampling of the research services that we offer. Whether it’s a dedicated HTS project profiling thousands of compounds, or the production of a novel multi-color reporter cell line, we have the tools and skills to take on your project. Want to take a summer break and come back to data – we’ve got your back!